MRIs Plus Mammograms Best for High-Risk Women?
Canadian researchers say combination better for those at risk of breast cancer
By Kathleen Doheny
TUESDAY, June 17, 2014 (HealthDay News) -- For the best chance at spotting breast cancer early, women at high risk need frequent MRI screenings along with mammograms, a large Canadian study contends.
Mammograms alone failed to detect the early cancers in a study of more than 2,000 high-risk women, according to the findings.
"What my study is showing is that high-risk women should be screened earlier, beginning at the age of 30," said study researcher Anna Chiarelli, a senior scientist at Cancer Care Ontario. "They should be screened often -- every year -- and they should be screened with both a breast MRI and a mammogram every year."
Chiarelli and her colleagues followed 2,207 women, aged 30 to 69, all at high risk of breast cancer, to determine the effect of the two screenings. The women were enrolled in the Ontario Breast Screening Program, which expanded in July 2011 to screen high-risk women in a special program that uses both tests -- MRI and digital mammography.
The women were viewed as high risk mainly if they had a known genetic mutation in the BRCA 1 or 2 gene, or other breast cancer-related genes; if they had not been tested for the mutations but had a first-degree relative with them; if they had a family history of breast cancer and personally had a 25 percent or higher lifetime risk; or if they had radiation therapy before age 30.
The first-year results of the high-risk program turned up 35 breast cancers. None of them was detected by mammogram alone; 23 were detected by MRI alone, and another dozen were picked up from both screenings.
"If we only had offered these women mammograms, we would not have found 23 of these breast cancers," Chiarelli said.
In some cases, the mammogram was positive, in others, it was negative, she added. But in all the cases of breast cancer diagnoses, the MRI was positive.
The study is published in the June 16 online edition of the Journal of Clinical Oncology.
Some U.S. experts, including those at the American Cancer Society, also recommend both tests for high-risk women.